Macitentan: entry-into-humans study with a new endothelin receptor antagonist
Open Access
- 4 May 2011
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 67 (10), 977-984
- https://doi.org/10.1007/s00228-011-1043-2
Abstract
To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor antagonist, in healthy male subjects. This double-blind, placebo-controlled study was performed in seven groups of eight healthy male subjects. Doses of 0.2, 1, 5, 25, 100, 300 and 600 mg or placebo (two subjects per group) were administered. Plasma macitentan and endothelin-1 and serum total bile salt concentrations were measured and analysed non-compartmentally. Plasma and urine were analysed qualitatively for the presence of metabolites and one of these, ACT-132577, was also measured quantitatively in plasma. Standard tolerability measurements were performed throughout the study. Macitentan was slowly absorbed and, at a dose of 300 mg, the t1/2 (95% confidence interval, CI) was 17.5 h (14.1, 21.8). The dose-proportionality coefficient β for Cmax (95% CI) was 0.83 (0.79, 0.87) indicating less than dose-proportional pharmacokinetics of macitentan. In plasma, a pharmacologically active oxidative depropyl metabolite, ACT-132577, was found whereas in urine two minor metabolites were detected. The t1/2 of ACT-132577 (95% CI) was 65.6 h (53.1, 80.9). Macitentan dose-dependently increased endothelin-1 concentrations up to 2.2-fold (95% CI 1.4, 2.4) at a dose of 600 mg, but had no consistent effect on total bile salts. Macitentan was well tolerated up to and including a dose of 300 mg, the maximum tolerated dose. Headache, nausea and vomiting were dose-limiting adverse events. The pharmacokinetic and tolerability profile of macitentan is consistent with a once-a-day dosing regimen and warrants further investigation in clinical studies.Keywords
This publication has 22 references indexed in Scilit:
- Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.Canadian Journal of Physiology and Pharmacology, 2010
- Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB ReceptorAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor AntagonistThe Journal of pharmacology and experimental therapeutics, 2008
- Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.Canadian Journal of Physiology and Pharmacology, 2008
- Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?European Heart Journal, 2008
- The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?British Journal of Pharmacology, 2008
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Influence of Food Intake and Formulation on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor AntagonistThe Journal of Clinical Pharmacology, 2002
- Transaminase elevation on placebo during Phase I trials: prevalence and significanceBritish Journal of Clinical Pharmacology, 1999
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994